| Autor: |
Vinicius Fontanesi Blum, Sérgio Cimerman, James R Hunter, Paulo Tierno, Acioly Lacerda, Alexandre Soeiro, Florentino Cardoso, Nancy Cristina Bellei, Juliana Maricato, Nathalia Mantovani, Marcella Vassao, Danilo Dias, Juliana Galinskas, Luis Mário Ramos Janini, Joanna Reis Santos-Oliveira, Alda Maria Da-Cruz, Ricardo Sobhie Diaz |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
EClinicalMedicine, Vol 37, Iss , Pp 100981- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2589-5370 |
| DOI: |
10.1016/j.eclinm.2021.100981 |
| Popis: |
Background: The absence of specific antivirals to treat COVID-19 leads to the repositioning of candidates’ drugs. Nitazoxanide (NTZ) has a broad antiviral effect. Methods: This was a randomized, double-blind pilot clinical trial comparing NTZ 600 mg BID versus Placebo for seven days among 50 individuals (25 each arm) with SARS-COV-2 RT-PCR+ (PCR) that were hospitalized with mild respiratory insufficiency from May 20th, 2020, to September 21st, 2020 (ClinicalTrials.gov NCT04348409). Clinical and virologic endpoints and inflammatory biomarkers were evaluated. A five-point scale for disease severity (SSD) was used. Findings: Two patients died in the NTZ arm compared to 6 in the placebo arm (p = 0.564). NTZ was superior to placebo when considering SSD (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
